

# **Title: An Overview of Clinical Applications of 3-D Printing and Bioprinting**

## **Background**

In the 1980s, the first 3-D printing (3-DP) patent was filed by Charles Hull.<sup>1</sup> Since then, substantial hype and growing demand has developed around a technology class that some anticipate will fundamentally change manufacturing across industries.<sup>2-5</sup> Promising medical solutions such as bionic limbs, replacement organs, and advanced pharmaceutical delivery systems have been conceived, yet technical, scientific, and regulatory challenges persist. While some medical applications of 3-DP are diffusing into practice, many remain in the exploratory research and development phase.<sup>6</sup> This bulletin provides an overview of clinical applications of 3-DP and bioprinting, including the current context in Canada and other countries, emerging technology developments, potential implementation issues, and challenges for the assessment and evaluation of 3-DP technologies.

### ***What is 3-D Printing?***

Additive manufacturing or 3-DP is the process by which 3-D objects are created, layer-by-layer, from raw materials such as guided by a digital file.<sup>7-10</sup> Although there is some disagreement in 3-DP terminology,<sup>11</sup> generally, additive manufacturing describes large scale, industrial grade printers used to print at a commercial scale, whereas 3-DP describes smaller printing using consumer-grade printers (e.g. for rapid prototyping or models).<sup>7</sup> This bulletin uses the term 3-DP to describe both approaches.

In health care, there is great interest in 3-DP as a tool that may help clinicians, health care administrators, and device manufacturers to:<sup>12-16</sup>

- visualize and plan complex interventions,
- create personalized or patient-specific devices,
- build devices of complex internal and external shape and structure from biocompatible materials,
- produce devices or supplies on-site as needed,
- streamline supply chains,
- reduce inventory needs,
- reduce labour costs

3-DP may also appeal to health care providers who regularly use small parts suitable for printing (e.g. dental crowns)<sup>15</sup> and promises to help move health care from its current one-size-fits-all approach to small batch or even patient specific medical devices.<sup>16</sup>

3-DP is an active area of research with many studies underway. At the time of the grey literature search for this bulletin, more than 100 clinical trials of clinical applications of 3-DP were registered as in progress or recruiting in the International Clinical Trials Registry Platform<sup>17</sup> and ClinicalTrials.gov<sup>18</sup> and 14 systematic reviews of 3-DP applications in health care were registered in PROSPERO.<sup>19</sup>

### ***What is Bioprinting?***

Part of a complex process known as biofabrication, bioprinting is a 3-DP technique that combines living cells (e.g. stem cells) and supportive biomaterials (e.g. scaffolds on which cells

46 can grow) into so-called bioinks.<sup>13,20,21</sup> These bioinks are printed into pre-specified computer-  
47 generated designs with the goal of eventually maturing into specific tissues.<sup>13,20,21</sup>

48  
49 Driven in part by a lack of donor tissues and organs,<sup>22</sup> advances in “bioprinting instrument  
50 capabilities; printing speed and precision; better preservation of living cells pre- and post-  
51 printing; printing multiple bioinks together; and innovations in bioink and support material  
52 formulations allowing printing of soft flexible tissue materials”<sup>23</sup> are helping grow research and  
53 development in the field.

54  
55 While *in vivo* work in regenerative medicine is still in very early stages of research — with full  
56 organ transplant seen as the long-term goal<sup>23</sup> — a number of companies around the world are  
57 actively working to improve bioprinting by expanding the types of materials and advancing  
58 technological approaches.<sup>24</sup>

## 59 **Scope**

60 In 2016 CADTH produced a brief horizon scan on 3-DP applications in health care.<sup>25</sup> The  
61 current bulletin expands on this work, focusing primarily on clinical applications of 3-D printing  
62 and bioprinting. Other health care applications of 3-D printing and bioprinting, including 3-DP of  
63 pharmaceuticals, are also discussed.

## 64 **Methods**

65 These bulletins are not systematic reviews and do not involve critical appraisal or include a  
66 detailed summary of study findings. Rather, they present an overview of the technology and  
67 available evidence. They are not intended to provide recommendations for or against a  
68 particular technology.

## 69 **Literature Search Strategy**

70 A series of limited literature searches were conducted using the following bibliographic  
71 databases: MEDLINE, Embase, and the Cochrane Library. Grey literature was identified by  
72 searching relevant sections of the *Grey Matters* checklist (<https://www.cadth.ca/grey-matters>).  
73 The searches were completed October 2018, and limited to English-language documents  
74 published after January 1, 2008. Regular alerts updated the search until project completion.  
75 Conference abstracts were excluded from the search results.

## 76 **Study Selection**

77 One author screened the literature search results and reviewed the full text of all potentially  
78 relevant studies. Studies were considered for inclusion if the intervention was a clinical  
79 application of 3-D printing or bioprinting. The final selection focused primarily on existing  
80 evidence syntheses including systematic reviews and meta-analyses. Studies providing direct  
81 cost data, narrative reviews, and expert commentaries were also included. Grey literature was  
82 included when it provided additional information to that available in the published studies  
83 selected.

## 84 **Peer Review**

85 A draft version of this bulletin will be peer-reviewed by a clinical expert.

## 86 **Stakeholder Review**

87 A draft version of this bulletin will be posted publicly for stakeholder review.

## 88 The Technology

89 Creating 3-DP objects and bioprinted objects can be done using a number of different  
90 production techniques that, in general, share the following common components.<sup>7,14,26</sup>

- 91 1. Data (e.g. images) for the design software to use
- 92 2. Computer software for modelling or designing
- 93 3. A computer controlled printer
- 94 4. Appropriate layering materials for producing the desired object.

95  
96 Common production techniques for 3-DP and bioprinting used in clinical applications are  
97 described in Table 1.

98 **Table 1 Description of Common Production Techniques for 3-D Printing and Bioprinting**

| 3-DP Techniques <sup>a</sup>  | Description and Considerations <sup>7,21,26-31</sup>  |
|---|---|
| <i>Vat Polymerization</i>   |   |
| Stereolithography (or SLA) <sup>27,28</sup>   | The oldest method of 3-DP. Uses a scanning laser to scan a reservoir of photosensitive liquid polymer (resin), selectively solidifying layers from the surface of the liquid based on the design data. As layers are hardened a movable build platform descends to increase the depth of the material. The process uses software-generated supports, which have to be removed from the finished product.  |
| <i>Powder-Bed Fusion</i>  |   |
| Selective laser sintering (SLS) <sup>28</sup>   | Uses a laser or electron beam to trace a 2-D slice in a bed of fine thermoplastic powder composed of a variety of materials (e.g., nylon, metals), heating the powder to the point that it fuses together. Once the 2-D slice is traced, a new layer of powder is added to repeat the process until the object is formed. Referred to as Direct Metal Laser Sintering when the process is applied to metal alloys. This process does not require a support structure. |
| Selective laser melting (SLM) <sup>29</sup>   | Similar to SLS but the powder is heated by the laser to the point that it fully melts creating a homogenous part. It may be used if you are only using a single metal powder. The material is stronger but the porosity cannot be controlled.   |
| Selective heat sintering (SHS) <sup>32</sup>  | Similar to SLS but uses a thermal print head as opposed to a laser to sinter the powder. It allows the printer to be smaller in size.   |
| <i>Material Extrusion</i>   |   |
| Fused deposition modelling (FDM) <sup>28</sup><br><i>Also referred to as fused filament fabrication (FFF)</i> | Forms an object using a computer-controlled extrusion nozzle to deposit layers of heat-softened polymer melted from a filament.   |
| <i>Material Jetting</i>   |   |
| Polyjet <sup>30</sup>   | Uses inkjet technology to deposit photopolymer with an inkjet head that moves in the x and y-axes. Each layer is cured and successive layers are printed over top and fused. Products have high resolution, but may be weaker than other techniques.  |
| <b>Bioprinting Techniques</b>   |   |
| Extrusion-Based <sup>21</sup>   | Uses a robotic system to continuously extrude bioinks in one long filament onto a scaffold. Forces created by the extrusion may impede cell survival, but the resulting structures are more mechanically-robust than other methods  |
| Droplet-Based <sup>21</sup>   | Bioinks are placed, drop-by-drop, into precise positions using a variety of techniques to form a 3-D shape. Cells have good viability and the technique is relatively rapid and high resolution – limitations include the potential for variation in droplet size and clogging of the nozzle.   |
| Laser-Based <sup>21,31</sup>  | Uses laser energy absorption to propel cell hydrogel droplets to a surface. Compared to other methods it has good cell viability and minimal clogging but is more expensive and time-consuming to do high resolution.   |

<sup>a</sup>This is not a comprehensive list of 3-D printing technologies; rather, some examples of approaches used in clinical applications  
3-DP = 3-dimensional printing

102 Regardless of the technique used for printing, production of 3-DP objects (including medical  
 103 devices) involves three general steps: pre-processing, printing, and post-processing.<sup>7,26,33</sup>  
 104 Bioprinting follows a similar production path but with some notable differences throughout the  
 105 process.<sup>21,23</sup> These production steps (with additional considerations for bioprinting) are  
 106 described in more detail in Table 2.

107  
 108 Other factors that may also be taken into consideration when producing a 3-DP object include:  
 109 1) Material selection, which depends on both the needs of the object being printed and the  
 110 requirements of the printing process and equipment being used.<sup>26</sup>  
 111 2) Design considerations beyond the object itself such as support structures and thickness of  
 112 layered materials.<sup>26,33</sup>

113  
 114 **Table 2: A General Approach to Production of 3-D Printed Objects and Considerations for**  
 115 **Bioprinting**

| Production Step | 3-D Printing   | Bioprinting Considerations   |
|-----------------|--|--|
| Pre-Processing  | <ul style="list-style-type: none"> <li>• Acquire images (e.g. from MRI or CT)<sup>7,33</sup></li> <li>• Convert images into files the printer can use (e.g. computer-aided design files<sup>a</sup> or additive manufacturing files).<sup>26,33</sup></li> <li>• Select design inputs (e.g. “surface characteristics, object rigidity...reaction to external forces applied during use”)<sup>26</sup></li> </ul> | <ul style="list-style-type: none"> <li>• May include:               <ul style="list-style-type: none"> <li>○ collection of tissue samples (for a source of autologous cells),</li> <li>○ work with stem cell lines,</li> <li>○ developing processes for biomimicry (to allow for cell growth)<sup>21</sup></li> </ul> </li> </ul>  |
| Printing        | <ol style="list-style-type: none"> <li>1) Select layering material(s)<sup>7,26</sup> (e.g. metal, plastic, ceramic, glass, liquid, and living cells [used for bioprinting])</li> <li>2) Select an approach to printing<sup>7,26-28</sup></li> </ol>  | <ul style="list-style-type: none"> <li>• Printing materials are bioinks,<sup>21,23</sup> a mixture of cells, growth matrix, and nutrients loaded into printing cartridges.<sup>23</sup></li> <li>• Certain methods can impede cellular growth and should be considered when selecting a bioprinting method.<sup>21,23</sup></li> <li>• Speed of printing is also important because cells cannot survive outside an incubator for long.<sup>23</sup></li> <li>• Cell material needs to interact and printing at a high resolution can facilitate this<sup>21</sup></li> </ul> |
| Post-Processing | <ol style="list-style-type: none"> <li>1) Remove any remaining support structures and residues<sup>26</sup></li> <li>2) Final quality assurance testing.<sup>26</sup></li> </ol>   | <ul style="list-style-type: none"> <li>• Focused on continued growth and development of the cells.<sup>21</sup></li> <li>• Structures must be loaded into an incubator and provided with appropriate biological conditions to grow into mature tissue.<sup>23</sup></li> </ul>   |

<sup>a</sup>Note: Design files can also be informed using lessons learned from previous product design.<sup>16</sup>

116  
 117  
 118 While the above production steps describe a typical approach to building a 3-D printed object  
 119 itself, manufacturers can use 3-DP to build “negative” structures for use as casts or molds.<sup>13</sup>

## 120 Emergence of 3-D Printing and Bioprinting in Canada

121 A 2017 report of Canada’s Standing Senate Committee on Social Affairs, Science and  
 122 Technology identified 3-DP as one of three areas anticipated to present challenges to the

123 Canadian health care system.<sup>34</sup> Presentations from Health Canada to the committee indicated  
124 that devices produced using 3-DP have already been approved for use in Canada.<sup>34</sup>

125  
126 Our search of the grey literature identified many examples of research, development, and  
127 production in 3-DP for health in Canada.<sup>35-45</sup> Examples of Canadian activities range from  
128 hospital scale printing,<sup>40</sup> academic initiatives and collaborations,<sup>37-39,44</sup> not-for-profit initiatives,<sup>35</sup>  
129 and for-profit start-ups and organizations.<sup>36,41-43,45</sup> A network of private, public, academic, and  
130 not-for-profit organizations, Canada Makes, “dedicated to promoting the adoption and  
131 development of advanced and additive manufacturing (AM) in Canada” includes a section  
132 dedicated to 3-DP in medicine and dentistry on its website.<sup>46</sup>

## 133 **Regulatory Considerations**

134 3-DP and bioprinting, as emerging and potentially disruptive health technologies, present  
135 challenges to existing regulatory frameworks, decisions around which could affect their adoption  
136 within the health system.<sup>47</sup> This section discusses approaches to 3-DP and bioprinting in  
137 Canada and around the world.

### 138 **Canada**

139 In Canada, medical devices produced using 3-DP are subject to the Medical Devices  
140 Regulations.<sup>48</sup> In August 2018, Health Canada announced it was beginning to develop guidance  
141 for manufacturers wishing to obtain licenses for 3-DP medical devices.<sup>47</sup> A draft guidance  
142 document was released for comment in October 2018 and final guidance is expected in spring  
143 2019.<sup>48</sup> Feedback on the guidance issued has been posted publicly by some stakeholder  
144 groups.<sup>49</sup>

145  
146 The guidance is intended for manufacturers (including hospitals producing 3-DP devices for  
147 distribution outside their organization) of Class III and Class IV implantable medical devices.<sup>48</sup> It  
148 does not “provide guidance on third-party software, custom-made devices, patient-specific  
149 anatomical models, devices manufactured at point-of-care, and devices with biological  
150 components.”<sup>48</sup> It is unclear whether future guidance will address these topics.

151  
152 Health Canada’s draft guidance notes that production of 3-DP devices presents unique  
153 considerations for manufacturers and that, in addition to the data required for approval of all  
154 Class III and Class IV medical devices, additional information may be required for approval of 3-  
155 DP medical devices.<sup>48</sup> For example:

- 156 • Manufacturers must specify the starting materials, any additives, and the 3-DP technique  
157 used for production.
- 158 • Manufacturers must indicate if all or part of the device is 3-DP
- 159 • Submissions must include a design philosophy explaining why 3-DP was the appropriate  
160 manufacturing approach
- 161 • Records of printer maintenance and cleaning, validation of consistent performance, the  
162 accuracy of reproduction of patient-specific images, and validation of printer-material  
163 combinations must be kept
- 164 • Processes for removal and possible reuse or recycling of layering materials must be  
165 validated
- 166 • Verification and validation of the software for design and printing is required
- 167 • Biocompatibility of finished devices must be completed after manufacturing as the  
168 variability of processes during the printing process may affect even biocompatible  
169 materials
- 170 • Processes for post-processing removal of residues and excess layering material and  
171 sterilization of 3-DP devices must demonstrate that bioburden is minimized and consider  
172 how sterilization may affect the final product.

173 **United States**

174 In recognition of the wide range of 3-DP applications, the FDA regulates technologies as either  
175 medical devices, biologics, or drugs.<sup>9</sup> As of December 2017 more than one hundred 3-DP  
176 devices currently on the market had been reviewed by the FDA.<sup>50</sup>  
177

178 Initial FDA guidance for 3-DP medical devices was issued in 2017, acknowledging the unique  
179 design, manufacturing, and device testing requirements.<sup>10</sup> Bioprinting is not included in this  
180 guidance.<sup>10</sup> The document covers technical considerations for quality systems based on  
181 regulatory classification and associated regulation to which the device is subject, as well as  
182 manufacturing considerations, and the information required for regulatory notifications and  
183 submissions.<sup>10</sup> It is meant to supplement, not replace, other applicable regulatory guidance for  
184 medical devices.<sup>10</sup> The FDA noted that this guidance will evolve as understanding develops on  
185 factors such as non-traditional manufacturing sites and supply chains, the use of biological  
186 printing material,<sup>20</sup> and point-of-care device considerations.  
187

188 The FDA also conducts primary research on 3D printing at several sites to help understand its  
189 impact on the safety and quality of medical technologies.<sup>10</sup> Findings from this research aim to  
190 inform policy development and guidance updates.<sup>10</sup> Support for innovation and access is offered  
191 through the *Emerging Technology Program*,<sup>51</sup> which allows early engagement with  
192 manufacturers hoping to bring their 3D printing technologies to market.<sup>10</sup>

193 **Europe**

194 In Europe regulation of 3-DP health technologies is complex and is governed by (as of 2017)  
195 three frameworks: European Medical Devices Directive, the In Vitro Diagnostic Medical Devices  
196 Directive, and the Active Implantable Medical Devices Directive.<sup>14</sup> Regulation is dependent on  
197 the type of device being printed (i.e. patient-specific, customizable, or mass produced)<sup>14</sup>  
198 Consideration must also be made for the printer, software, and materials used.<sup>14</sup> Hospital-made  
199 devices are exempt from some regulations provided no equivalent product exists, the hospital  
200 isn't mass producing items, and quality manufacturing standards are maintained.<sup>14</sup>

201 **Lack of Fit-For-Purpose Regulatory Frameworks for Bioprinting**

202 Bioprinting does not fit within existing regulatory frameworks or guidance.<sup>20</sup> It spans several  
203 areas of health care including but not limited to regenerative medicine, medical devices, and  
204 biologic drugs making it difficult to apply existing systems.<sup>20</sup> The customized single patient-use  
205 nature of bioprinted interventions suggests a potential exemption from, or the ability to  
206 circumvent, regulatory processes.<sup>20</sup>  
207

208 The exclusion of bioprinting from existing FDA guidance and the lack of a dedicated regulatory  
209 framework pose challenges in understanding the applicability of current regulatory requirements  
210 and addressing the uncertainty of harms.<sup>20,52,53</sup> Many countries have noted challenges in trying  
211 to develop a dedicated framework.<sup>20</sup> It is unclear whether bioprinted interventions will receive  
212 balanced consideration of their efficacy and safety without the presence of a tailored regulatory  
213 process.<sup>20</sup>

214 **Other Considerations**

215 Our literature search identified a number of other possible questions and considerations for the  
216 regulation of 3-DP medical devices for example:  
217

- 218 • What are the biocompatibility needs for materials used for 3-DP medical instruments  
219 (e.g. surgical guides)? If the needs are less than 3-DP implantable devices, does this  
220 open up the possibility of using different products and materials?<sup>13</sup>

- 221 • A 2016 systematic review of surgical applications of 3-DP noted that, for hospitals  
222 wishing to produce their own devices and equipment, regulatory requirements are a  
223 concern and might prevent 3-DP from being adopted.<sup>54</sup>  
224 • If there are requirements to label and be able to track medical devices, how does this  
225 work for custom 3-DP devices?<sup>14</sup>

## 226 Who Might Benefit?

227 It has been suggested that 3-DP will bring advantages to many aspects of health care such as  
228 diagnostics (using medical imaging to create models that aid in visualization), surgical planning,  
229 and personalized medicine.<sup>7</sup> Applications of bioprinting may disrupt existing models of organ  
230 and tissue donation, although these applications are likely further in the future than other 3-DP  
231 applications.<sup>7</sup> As presented in the following section, many clinical areas are currently using or  
232 investigating the use of 3-DP. Because of this, 3-DP has the potential to affect Canadians living  
233 with many different health conditions.

## 234 Clinical Applications of 3-D Printing

235 Initially reserved for complex cases, 3-DP is becoming more common or routine in some clinical  
236 areas.<sup>55</sup> A 2018 narrative review of registered clinical trials found orthopedics, dentistry, and  
237 maxillofacial surgery to be the most active areas of ongoing research<sup>56</sup>

238  
239 Based on our literature review, researchers generally organize 3-DP health care applications  
240 into the following categories of applications.<sup>8,13,14,26,28,57,58</sup>

- 241 • Anatomical models (e.g. for surgical preparation, planning, or to aid diagnosis)
- 242 • Surgical guides
- 243 • Tools and instruments
- 244 • Implants and therapeutic devices
- 245 • Prosthetics
- 246 • Tissues and organs
- 247 • Dental applications

248  
249 A 2018 report by KCE Belgium further classified 3-DP medical devices into three types based  
250 on their degree of personalization:<sup>14</sup>

- 251 • Custom-made medical devices (i.e. devices unique to an individual)
- 252 • Customizable medical devices (i.e. mass produced using a standard process and  
253 individualized to specific patients)
- 254 • Standard medical devices (i.e. mass produced using 3-DP because of device complexity  
255 or to lower costs)

256  
257 Our literature review identified publications about clinical 3-DP in the following clinical areas:  
258 dentistry, prosthetics and orthotics, and surgery. Because of overlap between clinical specialties  
259 (e.g. oral surgery and dentistry) some applications are discussed in more than one section.

### 260 **Dentistry**

261 Advances in dental imaging (such as cone beam CT) have resulted in increased interest in 3-  
262 DP for dentistry.<sup>59</sup> Our literature search identified 3-DP applications throughout dentistry  
263 including:

- 264 • Orthodontics<sup>7,60</sup> (for making and positioning brackets as well as aligners)
- 265 • Dental crowns and partial dentures<sup>27,61</sup>
- 266 • Removable complete dentures<sup>61,62</sup>

- 267 • Oral surgery<sup>60</sup>
- 268 ○ Surgical guides placed over teeth to align drills<sup>27,59</sup>
- 269 ○ Access guides for root canals<sup>59</sup>
- 270 ○ Replica teeth to prepare autotransplantation sites<sup>59</sup>
- 271 ○ Dental implants<sup>60</sup>

## 272 **Prosthetics and Orthotics**

273 Research in both prosthetics (devices that replace missing body parts) and orthotics (the design  
274 of external devices that modify the structure and function of the body) suggests potential  
275 benefits of using 3-DP. These include:

- 276 • Customization to offer better fit and ability to adjust or increase device functionality.<sup>13,55,63</sup>
- 277 • Lighter weight<sup>55</sup>
- 278 • Lower costs to make the devices available to a broader market.<sup>13,55,63</sup>

279 These potential benefits are of particular interest for children who can quickly outgrow  
280 expensive devices.<sup>55</sup>

281  
282  
283 A 2018 systematic review of 3-DP for upper limb prostheses included eight non-randomized  
284 studies.<sup>63</sup> The authors found that some of the studies focused on the printing process itself and  
285 did not report on patient-important outcomes. The authors also noted open source public  
286 databases — where 3-DP design files can be shared — are growing in popularity. However,  
287 their value has not been assessed at this time.<sup>63</sup>

288  
289 3-DP has also been used to produce customized earshells (a device that connects a hearing  
290 instrument to a person's ear canal) for hearing aids.<sup>15</sup>

## 291 **Surgery**

292 In surgery, the purported benefits of 3-DP are to provide surgeons with a better understanding  
293 of complex anatomy (when planning surgeries), allow for customized or patient-specific implants  
294 and surgical guides, and ultimately reduce operating room time.<sup>54,64</sup> A 2016 systematic review of  
295 3-DP in surgery identified and analyzed 10 years of discussion about advantages and  
296 disadvantages to using this approach.<sup>54</sup> The authors summarized advantages (such as shorter  
297 operative time, and reduced costs) and disadvantages to 3-DP (such as reactions to the  
298 material used, and added planning time).

299  
300 A 2015 narrative review of surgical applications of 3-DP grouped them in the following  
301 categories:<sup>28</sup>

- 302 • Anatomic models<sup>58</sup> (for pre-operative planning)
- 303 • Surgical instruments
- 304 • Implants and prostheses, splints and external fixators<sup>58</sup>

305  
306 A 2016 narrative review of surgical applications of 3-DP noted that although most imaging was  
307 conducted using CT and MRI “a number of other 3D imaging options have been used in 3D  
308 printing, such as: cone beam CT, CTA [CT angiography], MRA [magnetic resonance  
309 angiography], PET [positron emission tomography], MRCP [magnetic resonance  
310 cholangiopancreatography], 3D echocardiography, 3D laser scanning systems, and even  
311 images captured on an iPhone.”<sup>58</sup>

312  
313 A 2016 systematic review of 3-DP in surgery found most research was about surgical guides,  
314 models for surgical planning, or custom implants.<sup>64</sup> Orthopedics was the most published area  
315 and within that, knee surgery. Maxillofacial surgery is also an active area of research,



316 particularly in cranial and spinal surgery.<sup>64</sup> Studies about dental surgery, cardiovascular surgery,  
 317 cerebrovascular surgery, otolaryngology, and general surgery were also found.<sup>64</sup>

318  
 319 Examples of surgical applications of 3-DP are discussed, by subspecialty, in the following  
 320 sections.

321 **Neurosurgery**

322 In neurosurgery, advances in imaging have been beneficial to patient care by allowing clinicians  
 323 to observe small and intricate structures inside the nervous system.<sup>65</sup> 3-DP offers the potential  
 324 of improved visualization of the relationship between complex structures when planning a  
 325 procedure.<sup>65</sup> Because the spine has complex anatomy and is surrounded by delicate structures,  
 326 3-DP models and devices that help surgeons plan and accurately execute procedures could  
 327 also help improve patient outcomes.<sup>66</sup>

328  
 329 A 2016 systematic review of 3-DP in neurosurgery<sup>65</sup> included 36 studies focused in three areas:  
 330 patient-specific anatomical models, the design of devices to assess and treat neurosurgical  
 331 conditions, and biological tissue-engineered implants. In addition, a 2017 systematic review  
 332 included 54 studies addressing the status of 3-DP in spinal surgery.<sup>66</sup> Based on these reviews,  
 333 subspecialty 3-D printing applications in neurosurgery are listed in Table 3.<sup>65,66</sup> The spinal  
 334 surgery review noted that, as case complexity increased, so did the benefits of using 3-DP such  
 335 as reduced operative time and perioperative blood loss. 3-DP surgical guides were reported to  
 336 help mitigate risks of procedures.<sup>66</sup>

337  
 338 **Table 3 Subspecialty Applications of 3-DP in Neurosurgery<sup>65</sup>**

| Subspecialty                  | Application                                   | Example  |
|-------------------------------|---|--|
| Cerebrovascular <sup>65</sup> | Surgical planning and modelling               | Cerebral aneurysm surgery  |
| Neuro-oncology <sup>65</sup>  | Surgical planning and modelling               | Visualization of the relationship between skull, tissue, and tumour for resection – including incorporating information from fMRI                            |
|                               | Neurosurgical devices                         | Proton range compensator – to protect tissues away from the tumor  |
| Functional <sup>65</sup>      | Surgical planning and modelling               | Placement of intracranial electrodes for treatment-resistant epilepsy  |
|                               | Neurosurgical devices                         | Patient-specific head casts to reduce movement when monitoring brain activity  |
| Spinal <sup>65,66</sup>       | Neurosurgical devices <sup>65,66</sup>        | Patient-specific screw guides for optimizing the trajectory of pedicle screws used for spinal fixation   |
|                               | Custom implants                               | Used in complex cases (e.g., for congenital malformations or replacement of whole vertebrae) where an individualized approach is important for the prognosis |
|                               | Mass-produced implants <sup>66</sup>          | Devices with improved geometry and control of porosity and roughness for better osteointegration   |
|                               | Biological implants <sup>65</sup>             | Early research into implants to replace intervertebral disks instead of spinal fusion.   |
|                               | Surgical planning and modelling <sup>66</sup> | Used to provide a more complete  |

|  |  |  |
|--|--|--|
|  |  | understanding of the pathology and to simulate the procedures. |
|--|--|--|

339 **Orthopedics**

340 3-DP in orthopedics is an active area of research with a 2018 review of published work<sup>67</sup>  
 341 identifying several hundred publications and a 2018 review of registered clinical trials identifying  
 342 orthopedics as a top area of ongoing work.<sup>56</sup> Applications include using anatomic models to  
 343 visualize and plan for fracture repairs,<sup>22,68</sup> create implants for arthroplasty,<sup>22</sup> prepare contour  
 344 plates and surgical guides,<sup>55</sup> and create lightweight, custom casts.<sup>22</sup>  
 345

346 A 2018 systematic review comparing 3-DP with non-3-DP for tibial plateau fractures identified  
 347 15 studies, including 10 randomized controlled trials.<sup>68</sup> The authors noted that because these  
 348 fractures occur in complex anatomy (and involve an articular surface) visualizing the injury is  
 349 difficult. 3-DP could help overcome pre-operative planning challenges related to visualizing the  
 350 injury. Outcomes reported included operating time, intraoperative blood loss, time to bony union,  
 351 follow-up functional outcomes, and complications.  
 352

353 A 2018 narrative review of 3-DP applications in limb and pelvic injuries identified studies on a  
 354 wide range of applications including approaches to repair damage to many bones of both the  
 355 upper and lower extremities, including those of the hands and feet.<sup>55</sup>

356 **Vascular and Endovascular Surgery**

357 In vascular and endovascular surgery, 3-DP applications focus on visualization of anatomical  
 358 structure.  
 359

360 A 2018 systematic review of the “technical aspect, practicability, and clinical impact” of 3-DP in  
 361 vascular and endovascular surgery included 42 articles, mostly case reports and no randomized  
 362 controlled trials.<sup>69</sup> The authors found applications of 3-DP models primarily for infrarenal and  
 363 juxtarenal arteries, abdominal aortic aneurysm, and thoracic aorta pathology.<sup>69</sup> While older  
 364 studies reported on 3-DP of large vessel pathologies to better understand anatomy and post-  
 365 surgical complications, more recent publications include small and medium-sized vessels. The  
 366 authors noted that materials used have evolved from simple silicon rubber to materials such as  
 367 nylon and silica-based.

368 **Plastic and Reconstructive Surgery**

369 3-DP is being studied and used in plastic and reconstructive surgery for procedural planning,  
 370 the creation of surgical tools, and customization of implants.  
 371

372 A 2017 review<sup>70</sup> of the utility of 3-DP in maxillofacial surgery, dental implant surgery, mandibular  
 373 reconstruction, orthognathic surgery, and midface reconstruction found 100 articles and  
 374 categorized the most common applications into five categories: anatomic models, surgical  
 375 guides (most common application), occlusal splints, patient-specific implants, and facial  
 376 epithesis. Similar applications are noted in a 2018 review of orthognathic surgery.<sup>71</sup>  
 377

378 In a 2016 systematic review of ongoing and existing research on 3-DP applications in plastic  
 379 and reconstructive surgery,<sup>72</sup> the authors noted that increased availability of affordable 3-D  
 380 scanning technology resulted in the ability of clinicians to make highly patient-specific products.  
 381 Applications in the included articles reported by the authors included surgical planning; upper  
 382 limb and hand prosthetics; facial reconstruction; breast reconstruction; ear, nose and cartilage  
 383 reconstruction; and skin grafting.<sup>72</sup>  
 384

385 A 2015 review of clinical applications of 3-DP in craniofacial surgery<sup>73</sup> noted its use in skull  
386 reconstruction, repair of orbital fractures, and orthognathic procedures.

### 387 **Hepatobiliary Surgery**

388 Applications of 3-DP in hepatobiliary surgery include models for surgical planning for liver  
389 surgery, including as a supplement to medical imaging.

390  
391 A 2018 systematic review of the clinical value and application of 3-DP in liver surgery<sup>74</sup> included  
392 19 (mostly case) studies of printing models to plan for surgery.<sup>74</sup> The authors noted that, in  
393 some reports, the studies used printed models that were reduced in size because of costs.<sup>74</sup>  
394 The authors also noted a wide range of model printing times —11h-100h for printing with some  
395 taking weeks to be printed and delivered.<sup>74</sup>

396  
397 A 2017 systematic review of 3-DP applications in liver surgery included 14 articles that  
398 examined the purpose of printing, how images were obtained and methods for printing in its  
399 analysis.<sup>75</sup> Production of models was used as an adjunct or alternative to imaging. The authors  
400 theorized that there is interest in this field because of the complex, unique anatomy involved in  
401 procedures such as liver transplant or cancer resection.<sup>75</sup>

### 402 **Urology and Renal Surgery**

403 In urology and renal surgery, 3-DP models are used for visualization to assist diagnosis, and  
404 structural visualization to plan for surgery, transplantation and other procedures.

405  
406 A 2018 systematic review of 3-DP applications in renal surgery<sup>76</sup> — specifically the clinical value  
407 of 3-DP to visualize renal tumours for removal — included 15 studies. The authors noted CT  
408 was the most common approach to acquiring images.

409  
410 A 2018 review of 3-DP in urology surgery<sup>77</sup> found studies reporting use for pre-surgical planning  
411 to remove renal masses; building molds to visualize the renal collection system for patients with  
412 kidney stones (to facilitate novel treatments), and to produce models of a donor's kidney and  
413 pelvic cavity to plan a kidney transplant. For prostate conditions, the authors noted 3-DP models  
414 were used along with MRI to diagnose prostate cancers, to help plan prostate surgery, and to  
415 plan complex urologic surgeries.<sup>77</sup>

416  
417 Another 2018 review of 3-DP applications in urology cancer<sup>78</sup> noted the use of anatomical  
418 models for planning and surgical simulation.

### 419 **Cardiac Surgery**

420  
421 Surgical planning is noted as a potential application of 3-DP in cardiac surgery. A 2018  
422 systematic review looked at the use of 3-DP heart models for surgical planning for people with  
423 congenital heart defects.<sup>79</sup> The review included 28 reports, mostly case reports and case series.  
424 The authors noted MRI was most common imaging modality used to acquire images.<sup>79</sup>

### 425 **Anesthesiology**

426  
427 A 2017 systematic review of 3-DP applications in anesthesiology (included 8 studies) found 3-  
428 DP was used to produce anatomic models to pre-operatively size airway devices and plan for  
429 airway management.<sup>80</sup> Biosorbable airway splints have also been produced using 3-DP.<sup>80</sup>

430

## 431 **Clinical Applications of Bioprinting**

432 Development in the field of bioprinting is being driven largely by “[medical needs of] aging  
433 populations; increasing unmet demand for organ donors; trends towards non-animal testing on  
434 therapeutics using 3-D cell culture platforms; clinical needs in wound care; and joint repair and  
435 replacement surgeries.”<sup>23</sup>

436  
437 Bioprinting is being explored for the purposes of repair, replacement, or regeneration to develop  
438 an assortment of tissues including: cartilage, bone, skin, periodontal tissues, other vascularized  
439 tissues, and cardiovascular tissues.<sup>13,81,82</sup> Bioprinted tissues are being investigated as analogs  
440 for toxicity testing, disease modelling, and for patient-specific drug screening, with the potential  
441 to eliminate testing on animals.<sup>13</sup>

442  
443 A 2018 narrative review of bioprinting applications noted the following areas in descending order  
444 of most to least developed and validated:<sup>23</sup>

445

- 446 • Tissue modelling (drug discovery and development)
- 447 • Toxicology testing (drug screening and cosmetics)
- 448 • Engineered tissues (regenerative med, prosthetics, and dental applications)
- 449 • Transplantation (full or partial organs as part of regenerative medicine)

## 450 **Other Health-Related Applications of 3-D Printing and** 451 **Bioprinting**

### 452 ***3-D Printed Medications***

453 Potential benefits of using 3-DP techniques to produce medications include the ability to:  
454 personalize a medication dose, combine the delivery of medications, and avoid the use of  
455 bulking agents or fillers that a person may be intolerant to (such as lactose).<sup>16</sup>

456

457 One example is Levetiracetam (a treatment for epilepsy), approved by FDA in 2015.<sup>7</sup> This  
458 product is produced using a 3-DP technique called Zipdose that combines powder and liquid  
459 printing to produce high-dose, quick-dissolving pills.<sup>83</sup>

460

461 A structured review of 3-DP of medications was published in 2013.<sup>84</sup>

### 462 ***Clinician Education and Training***

463 Examples of using 3-DP models to educate and train clinicians are common in the literature.  
464 Clinical areas where 3-DP training and education models are in use include pathology, urology,  
465 neurosurgery, vascular and endovascular surgery, congenital heart disease, and  
466 anesthesia.<sup>58,65,69,77-80,85</sup>

467

468 A 2018 systematic review of 3-DP in vascular and endovascular surgery discussed the potential  
469 of moving from a traditional learning model of “see-one, do-one, teach one” to an approach that  
470 includes simulation using 3-DP models<sup>69</sup>

471

472 3-DP could also be used to build a library of pathologies for future education.<sup>28</sup> However, the  
473 utility of practicing on such models, particularly those made from a single material, might not  
474 accurately replicate the feel of actual tissues.<sup>28</sup> Advances in 3-DP now allow for models to  
475 include different tissue types which may be more realistic as teaching models.<sup>85</sup>

476

477 While experienced clinicians may be able to clearly visualize internal structures, it is possible  
478 they could benefit from training using 3-DP anatomical models when preparing for complex  
479 interventions.<sup>13</sup>

### 480 ***Patient Education***

481 Using 3-DP models may help patients understand their condition (e.g. visualizing anatomy in  
482 congenital heart disease<sup>79</sup>), understand complex anatomy and procedures (e.g. during  
483 preparation for vascular surgery<sup>69</sup> or liver cancer resections<sup>78</sup>), and improve shared  
484 understanding when seeking informed consent.<sup>28,73</sup>

### 485 ***Other Applications***

486 3-DP is also used to produce phantoms (objects that are specially designed to be scanned or  
487 imaged) for testing imaging systems.<sup>86</sup>

## 488 **Implementation Issues**

489 The integration of 3-DP into routine clinical practice goes beyond the effectiveness and safety of  
490 the individual technologies. There are several potential implementation considerations related to  
491 technical features, cost, legal and ethical issues, and patient-related factors.

### 492 ***Technical Considerations***

493 There are a range of important considerations in the implementation of 3-DP related to factors  
494 such as the technological and manufacturing process, materials, and technical limitations of the  
495 technology.

496  
497 3-DP requires a minimum level of image and resolution quality.<sup>26,73</sup> Successful printing, which is  
498 especially challenging in specialized fields such as vascular surgery, can be very dependent on  
499 the quality of imaging and printers available.<sup>69</sup> There are also many software options available  
500 and care is needed to ensure errors do not occur when converting data from one file type to  
501 another.<sup>26</sup> A 2015 narrative review of 3-DP in craniofacial plastic surgery noted a need for  
502 software specifically designed for these clinical applications as a barrier to uptake in the field.<sup>73</sup>  
503 Issues with accuracy (poor image resolution) and artefacts (related to CT being unable to scan  
504 metal) were also noted by the authors.<sup>73</sup>

505  
506 Uncertainty about the materials used for 3-DP has also been raised. For example, a 2017  
507 narrative review of prosthodontic applications of 3-DP noted that more research into the  
508 mechanical properties of materials used and the final products themselves was necessary.<sup>61</sup>  
509 Concern has also been expressed about the limited availability of 3-DP compatible materials,  
510 which could limit the potential for its use in health care.<sup>13</sup> That is, common biocompatible  
511 materials are often unsuitable for 3-DP and common materials used in 3-DP are often not  
512 biocompatible.<sup>13</sup> Another issue raised is a need for better understanding of what material  
513 microarchitectures (internal structures) result in the best performance.<sup>13</sup> Further, authors of a  
514 systematic review of 3-DP in spinal surgery noted that 3-DP cannot replicate all surgically useful  
515 information (such as joint instability) and, unlike some types of imaging, cannot provide real-time  
516 information.<sup>66</sup>

517  
518 A 2017 narrative review of 3-DP use in maxillofacial surgery noted that although low-cost  
519 printers are available, studies reported that 3-DP was more frequently being outsourced to a  
520 commercial medical device manufacturer as opposed to being printed in-house.<sup>70</sup> The authors  
521 noted less complex printing for items such as anatomical models may be more suitable for in-

522 house 3-DP.<sup>70</sup> In the case of self-printing, patients may not receive the support needed to  
 523 maximize use of such a device.<sup>63</sup>

524 **Cost and Administration**

525 **3-D Printing**

526 The literature search aimed to identify cost-related information about 3-DP in health care. We  
 527 identified few studies that directly evaluated costs, however, many studies and reports discuss  
 528 them indirectly.

529  
 530 Typical costs of 3-DP include the printer, software, and materials.<sup>58</sup> Costs also depend on the  
 531 type of manufacturing (i.e. consumer versus commercial).<sup>64</sup> A 2018 systematic review of 3-DP in  
 532 liver surgery noted that only a portion of included studies discussed costs and that what was  
 533 reported was dependent on the technique and materials used.<sup>75</sup> A pilot study of 3-DP in  
 534 maxillofacial surgery considered variables such as operative time as related to pre-operative  
 535 planning and pre-contouring of osteosynthesis hardware, surgical complications, and estimated  
 536 procedural costs.<sup>87</sup>

537  
 538 A 2018 KCE Belgium report found there was not much information available on the cost-  
 539 effectiveness of incorporating 3-DP into clinical practice and noted they found no studies  
 540 reporting results in cost per quality-adjusted life year.<sup>14</sup> Similarly, a 2016 systematic review of 3-  
 541 DP applications in surgery noted that only about 10% of included studies discussed cost-  
 542 effectiveness.<sup>64</sup> However, the authors found mixed reporting about lower and increased costs of  
 543 using 3-DP in many of the included studies.<sup>64</sup>

544  
 545 While cost was identified as a barrier to 3-DP in many included studies in a 2016 systematic  
 546 review of surgical 3-DP, the authors noted cost is a concern when introducing any new health  
 547 technology.<sup>54</sup> The value of 3-DP may also be difficult to assess. For example, while the time  
 548 required for the 3-DP process may greatly exceed the time saved in the operating room from  
 549 using a 3-DP model or device, the cumulative savings in operating room costs are likely greater  
 550 than the additional expense required to produce 3-D printed tools.<sup>54</sup> It may also be difficult to  
 551 generalize costs across institutions because of different practices.<sup>54</sup> 3-DP may also allow for  
 552 inexpensive production throughout the life of a device with the first device as inexpensive as the  
 553 last, something that is uncommon with other forms of manufacturing where prototype models  
 554 may involve substantial costs.<sup>72</sup>

555  
 556 A number of articles identified reported direct cost information and considerations. These  
 557 examples are summarized in Table 5.

558  
 559 **Table 4 Examples of Reported Costs of 3-DP Clinical Applications**

| Clinical Specialty            | Application             | Reported Cost             | Considerations   |
|-------------------------------|-------------------------|---------------------------|--|
| Plastic surgery <sup>72</sup> | Custom printed implants | US\$10,000 to US\$15,000  | Noted outlier costs as low as US\$30   |
| Spinal surgery <sup>66</sup>  | Anatomic models         | US\$300 to over US\$1,000 | Cost of printing models would be in addition to standard surgical planning.<br><br>The authors also reported time costs associated with the two to five hours for required for printing but noted that these upfront costs to 3-DP may be offset by time savings in actual procedures. |

|   |                 |                         |   |
|---|-----------------|-------------------------|---|
| Vascular and endovascular surgery <sup>69</sup> | Anatomic models | US\$4 to US\$2,360      | N/A   |
|   | Printers        | US\$2,210 to US\$50,000 | One high-end industrial printer had a reported cost of €230,000 |
| Renal surgery <sup>76</sup>                     | Anatomic models | US\$100 to US\$1,000    | Cost depended on materials used.                                |
| Congenital heart <sup>79</sup>                  | Anatomic models | US\$55 to US\$810       | Costs were for life-sized models.                               |

560  
561  
562  
563  
564  
565  
566  
567  
568

Moving away from costs, a 2017 systematic review of 3-DP in liver surgery noted that 3-D modeling use is not widespread due to a lack of technicians with specialist knowledge in interpreting medical imaging.<sup>75</sup> Specialized knowledge needed by both radiologists and technicians includes: “anatomical structure segmentation (automatic, semiautomatic, or manual), virtual modeling, preparation for 3D printing, the printing process itself, and postprocessing.”<sup>75</sup> Clinical expertise is also important, and a 2018 systematic review of upper-limb prostheses noted that most examples were not printed by clinicians and there was poor fit as a result.<sup>63</sup>

### 569 **Bioprinting**

570 A 2018 review of the bioprinting process discusses affordability as a concern throughout  
571 production. The cost of bioinks depends on the materials used in their composition.<sup>21</sup> For  
572 example, bioinks cost more as the concentration of cells increases.<sup>21</sup> The high cost of current  
573 bioprinters may also be a barrier to wider adoption of bioprinting in clinical use.<sup>21</sup> The processes  
574 required for successful bioprinting, e.g. sterility, may also contribute to the expensive cost.<sup>21</sup> A  
575 2018 review of bioprinting skin noted costs included cells, scaffolds, and printers.<sup>82</sup> Other costs  
576 associated with bioprinting include post-processing (e.g. the need for bioreactors to grow the  
577 tissues).<sup>21</sup> Reported costs of bioprinters range from US\$500 to US\$200,000.<sup>21</sup>

### 578 **Legal Considerations**

#### 579 **Data Ownership and Privacy**

580 3-DP (particularly for custom or patient-specific devices) requires individual patient data.<sup>14</sup> The  
581 method of data collection and use must be taken into account when considering 3-DP as part of  
582 a patient’s care plan.<sup>14</sup> The use of computer-aided design files may lead to intellectual property  
583 disputes and privacy concerns,<sup>88</sup> and questions about a patient’s right to access and own their  
584 own data.<sup>14</sup> It is not yet clear who will own the computer-aided designs and medical images and  
585 the final products, particularly when biological material is utilized.<sup>88</sup> To ensure patient data is  
586 kept private, 3-DP systems must also have adequate cybersecurity protocols in place.<sup>26</sup>

#### 587 **Liability**

588 3-DP deviates from standard chains of production, distribution, and use making the question of  
589 who is the producer or manufacturer difficult to answer.<sup>14</sup> It is unclear whether responsibility for  
590 custom designed implant failure could fall to: the surgeon who designed the implant, the  
591 software engineer who built the design software, the printer manufacturer, or the manufacturer  
592 of the materials used for the final product.<sup>14</sup>

### 593 **Ethical Considerations**

594 Some of the novel features of 3D printing are associated with ethical questions or  
595 considerations. For instance, the ability of 3-DP to augment structures and functions of the  
596 human body suggests potential exploitation of this feature for human enhancement (e.g.,  
597 proactively replacing bones with 3-DP alternative materials for function and performance).<sup>89</sup>

598 There is excitement and hope surrounding 3D printing which may impact patient perceptions  
599 and expectations.<sup>90</sup> This must be weighed against the uncertainty regarding safety and efficacy  
600 and the ethics of offering experimental treatments.<sup>90</sup>

601  
602 Another concern is the shift towards a decentralized manufacturing process.<sup>91</sup> Current safety  
603 regulations rely on centralized manufacturing processes, and may not be sufficient if  
604 manufacturing occurs at point-of-care.<sup>91</sup> While some believe 3-DP may democratize access to  
605 personalized medicine others believe complex 3-DP products (e.g., replacement organs) may  
606 only be accessible by those with substantial resources.<sup>89</sup> This may depend on the funding and  
607 reimbursement structure and the type of product or application.

## 608 ***Bioprinting***

609 Ethical considerations, specifically related to the introduction of bioprinting have been  
610 summarized in a review by Gilbert et al.<sup>20</sup> The authors raise questions on several key topics  
611 including:<sup>20</sup>

- 612 • Whether there should be restrictions on what (i.e., material and products) can be  
613 bioprinted
- 614 • The risks and challenges associated with testing bioprinted technologies in humans
- 615 • Ethical questions of treatment irreversibility, loss of treatment opportunity and treatment  
616 replicability; and
- 617 • The lack of guidance frameworks for testing and regulation of bioprinting in humans

618 Additional relevant ethical issues in bioprinting have been reviewed by others.<sup>91,92</sup>

## 619 ***Restrictions to Bioprinting Materials and Products***

620 Bioprinting has generated interest for its potential role in reducing disease burden and health  
621 care costs,<sup>93</sup> but there is also the potential for bioterrorism<sup>94</sup> and unauthorized use by those with  
622 access to printing equipment.<sup>20</sup> Gilbert et al. noted the conflicting desire to provide access to  
623 potentially lifesaving treatments while avoiding doing harm in the face of uncertainty.<sup>20</sup> Further,  
624 the risks may differ depending on the product being printed and the bioink used for its  
625 creation.<sup>20</sup> There may be ethical concerns with administering bioprinted treatments of animal or  
626 embryonic origin to those with religious or other ethical conflicts.<sup>20</sup> The potential for donor  
627 coercion to supply biological materials was also noted.<sup>20</sup> The authors also touched on the  
628 potential implications of the origin of the material and the possibility that certain materials may  
629 carry a higher risk of harm (e.g., disease transmission) than others. General ethical concerns  
630 with tissue engineering may also apply in the case of bioprinting.<sup>20</sup>

## 631 ***Risk of Testing Bioprinting in Humans***

632 With respect to studying or testing bioprinted products in humans, Gilbert et al. noted that  
633 because of the nature of the bioprinted interventions, it is not feasible nor ethical to conduct  
634 safety trials using the traditional approach of testing the intervention in multiple subjects.<sup>20</sup> For  
635 each new application, the patient would likely be acting as the “guinea pig” for their  
636 personalized, and thus experimental treatment.<sup>20</sup> While it may be possible to standardize criteria  
637 and protocols, each treatment is unique and findings from one patient are not generalizable to  
638 the next.<sup>20</sup> Gilbert et al. suggested that adding therapeutic efficacy endpoints to earlier stage  
639 clinical trials, particularly when patients have life-threatening conditions, could increase the  
640 value of investigations in this context.<sup>20</sup> They also discussed the importance and challenge of  
641 obtaining transparent and comprehensive informed consent in an environment of substantial  
642 uncertainty, particularly given the hype and perception of lower risk when using autologous  
643 (patient is donor) material.<sup>20,95</sup>

644



645 To help patients make informed decisions about 3-DP technologies, KCE Belgium  
646 recommended “giving the patient complete information on the existing alternatives and as  
647 necessary on the scientific uncertainty that the 3D-printed medical device concerned would be  
648 safer or more effective than the existing alternative.”<sup>14</sup>  
649

650 *Irreversibility, Loss of Opportunity for Future Treatment, and Limited Replicability of Treatment*  
651 Patients may not have the same opportunity to withdraw from a trial after implantation of a  
652 bioprinted product.<sup>20</sup> Procedures may have limited reversibility, particularly when cells are  
653 inserted into an existing biological structure.<sup>20</sup> The inability to withdraw from a trial may limit the  
654 opportunity for access to future treatment, restricting patient autonomy.<sup>20,96</sup> Gilbert et al. (also  
655 citing others) raised the question of whether it is morally appropriate to implant bioprinted  
656 materials for safety testing given the uncertainty regarding the risk-benefit profile.<sup>20,97-99</sup> This is a  
657 concern given the current climate of extending experimental therapy opportunities in the  
658 regulatory context.<sup>20</sup> Further, treatment effects may not be replicable from patient to patient as  
659 the intervention will elicit a genetically, structurally, and phenotypically unique response.<sup>20</sup>

## 660 **Considerations for Evaluation and Assessment of 3-D** 661 **Printing and Bioprinting Technologies**

662 Organizations conducting secondary research and evaluations of 3-DP technologies may  
663 encounter certain challenges and opportunities. Among these are the quality and maturity of the  
664 evidence, unique features of 3-DP that may warrant alternative study designs and data  
665 collection measures, challenges associated with the customized nature of the technology, and a  
666 lack of consensus on nomenclature.

667 Authors of literature reviewed for this bulletin often expressed concern with both the quality and  
668 quantity of available evidence for 3-DP in health and a need for evaluation of relevant outcomes  
669 measures. For example:  
670

- 671
- 672 • A 2017 systematic review of 3-DP in health care found that only 14% of identified studies  
673 had a control group and over 40% were case reports. No randomized controlled trials  
674 were published outside maxillofacial surgery and few existing systematic reviews  
675 critically appraised the literature.<sup>8</sup>
  - 676 • A 2017 review of 3-DP applications in maxillofacial surgery noted claims of 3-DP  
677 increasing surgical precision and reducing surgical time are commonly made but not  
678 frequently evaluated.<sup>70</sup>
  - 679 • A 2018 ECRI “Hotline Response” on the use of 3-DP for surgical planning in  
680 cardiovascular and neurosurgery included few studies.<sup>100</sup>
  - 681 • A 2017 cost-effectiveness study of 3-DP applications in maxillofacial surgery noted that  
682 the types of cases where 3-DP would be most advantageous are rare and  
683 heterogeneous making it difficult to evaluate the value of incorporating 3-DP in to  
684 practice.<sup>87</sup>
  - 685 • A 2017 systematic review of 3-DP applications in spinal surgery concluded that much of  
686 the available evidence was from low-quality studies with biases that reflect the  
687 excitement of work in a new field.<sup>66</sup>
  - 688 • A 2017 systematic review of 3-DP applications in liver surgery noted a lack of studies  
689 validating the anatomical accuracy of 3-DP models in this field.<sup>75</sup>
  - 690 • A 2018 report by KCE Belgium of 3-DP in health noted “few demonstrated advantages  
691 for the patient and conflicting results with regard to reduction in operating time.”<sup>14</sup>
  - 692 • In the US, AETNA considers stereolithography to be experimental and investigational as  
693 this type of modelling has not been proven to improve surgical outcomes.<sup>101</sup>  
694

695 The state of evidence (or lack thereof) may be a barrier to adoption of 3-DP in health care.<sup>56</sup>  
696 However, evidence is not uniform across all fields, as a 2018 review of 3-DP trials registered in  
697 clinical trial registries noted surgical fields such as maxillofacial surgery, orthopedics, and  
698 cardiology appear more developed.<sup>56</sup> Furthermore, the same review noted a spike in registered  
699 3-DP trials after 2015, concluding that this may be an indication the technology is moving from a  
700 state of early ideas and research to one of more long term study.<sup>56</sup> As noted earlier, bioprinting  
701 is less developed than 3-DP with much of the existing body of literature focusing on *in vitro*  
702 experimentation and conceptual exploration.<sup>21</sup> In testimony to Canada's Standing Senate  
703 Committee on Social Affairs, Science and Technology, presenters commented that traditional  
704 randomized controlled trials may not be the most appropriate approach for assessing the safety  
705 and efficacy of innovative technologies like 3-DP and that alternatives should be considered.<sup>34</sup>  
706

707 The current quantity and quality of evidence and unique features of 3-DP may present  
708 challenges in conducting comprehensive evaluations of the technology. Specific challenges may  
709 exist for health technology assessment. In a project description and planning document for a  
710 health technology assessment on a 3-DP topic, EUnetHTA made note of several relevant  
711 considerations. These included but were not limited to inconsistency in regulatory and market  
712 access requirements, questions around the type of data collection needed to monitor long-term  
713 safety outcomes, challenges identifying specific manufacturers and low manufacturer  
714 engagement, lack of standardization of the device due to customization, and the need for a  
715 technical expert on the project.<sup>102</sup>  
716

717 A 2017 review of taxonomy and terminology used in 3-DP research found a wide range of terms  
718 are being used to describe these applications.<sup>11</sup> The authors noted that a consistent, common  
719 set of language is necessary for collaborative research and eventually for reimbursement of 3-  
720 DP technologies and proposed that "3D Printing" be adopted as the common term.<sup>11</sup> The lack of  
721 consensus on terminology could present challenges when evaluating 3-DP technologies using  
722 epidemiological methods that rely on literature searching and review strategies, such as health  
723 technology assessment and systematic reviews.

## 724 **Final Remarks**

725 Research on clinical applications of 3-DP and bioprinting has progressed, both in volume and  
726 stage of inquiry, with some applications exiting the exploratory phase and undergoing concrete  
727 clinical evaluation.<sup>8,56</sup> In parallel, there has been growth in Canadian and international initiatives  
728 in 3-DP<sup>35-45</sup>  
729

730 Hospitals and clinics stand to benefit from more rigorous research into the effectiveness and  
731 safety of 3-DP technologies.<sup>8</sup> Evidence could be made more robust through larger studies and  
732 greater consideration of the value of the technology.<sup>14</sup> Adopting a formal model, such as IDEAL  
733 (Idea, Development, Exploration, Assessment and Long-term study) suggested by KCE  
734 Belgium, may help address issues in data collection and help pave the way to further  
735 implementation and reimbursement of 3-DP in health care.<sup>14</sup>  
736

737 Areas that could help foster research and development of bioprinting include open sourcing of  
738 hardware and software, open innovation (greater use of external ideas and technologies for  
739 internal business, and greater sharing of internal ideas with external businesses<sup>103</sup>), and greater  
740 understanding of customer and market needs.<sup>23</sup>  
741

742 Looking beyond the current state of 3-DP, 4-D printing (an approach that "adds a dimension of  
743 transformation over time where printed products are sensitive to parameters like temperature,

744 humidity, time etc.”) may offer additional advantages in the medical field as smart implants,  
745 tools, and devices become more common.<sup>104</sup>

DRAFT

## 746 References

- 747 1. Hull CW. inventor; Apparatus for production of three-dimensional objects by  
748 stereolithography. US Patent US4,575,330; 1984.
- 749 2. Gartner. Hype Cycle for 3D Printing, 2018. 2018.
- 750 3. d'Aveni R. The 3-D printing revolution. *Harv Bus Rev.* 2015;93(5):40-48.
- 751 4. Petrick IJ, Simpson TW. 3D printing disrupts manufacturing: how economies of one  
752 create new rules of competition. *Research-Technology Management.* 2013;56(6):12-16.
- 753 5. Jamroz W, Szafraniec J, Kurek M, Jachowicz R. 3D Printing in Pharmaceutical and  
754 Medical Applications - Recent Achievements and Challenges. *Pharm Res.*  
755 2018;35(9):176.
- 756 6. Combellack E, Jessop ZM, Whitaker IS. 20 - The commercial 3D bioprinting industry. In:  
757 Thomas DJ, Jessop ZM, Whitaker IS, eds. *3D Bioprinting for Reconstructive Surgery:*  
758 Woodhead Publishing; 2018:413-421.
- 759 7. Jagadeesh V. Medical applications of 3D printing. *Pharma Times.* 2018;50(5):9-17.
- 760 8. Diment LE, Thompson MS, Bergmann JHM. Clinical efficacy and effectiveness of 3D  
761 printing: a systematic review. *BMJ Open.* 2017;7(12):e016891.
- 762 9. FDA. 3D Printing of Medical Devices. 2018;  
763 [https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/3DPrintingofMedic](https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/3DPrintingofMedicalDevices/default.htm)  
764 [alDevices/default.htm](https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/3DPrintingofMedicalDevices/default.htm). Accessed December 21, 2018.
- 765 10. FDA. *Technical Considerations for Additive Manufactured Medical Devices: Guidance*  
766 *for Industry and Food and Drug Administration Staff.* 2017.
- 767 11. Chepelev L, Giannopoulos A, Tang A, Mitsouras D, Rybicki FJ. Medical 3D printing:  
768 methods to standardize terminology and report trends. *3D Print Med.* 2017;3(1):4.
- 769 12. FDA. The 3Rs of 3D Printing: FDA's Role. 2016;  
770 <https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm533992.htm>.
- 771 13. Zadpoor AA, Malda J. Additive Manufacturing of Biomaterials, Tissues, and Organs. *Ann*  
772 *Biomed Eng.* 2017;45(1):1-11.
- 773 14. Vinck I, Vijverman A, Vollebregt E, et al. *Responsible use of high-risk medical devices:*  
774 *the example of 3D printed medical devices.* Brussels: Belgian Health Care Knowledge  
775 Centre (KCE);2018. 297.
- 776 15. Snyder GH, Cotteleer M, Kotrek B. *3D opportunity in medical technology : Additive*  
777 *manufacturing comes to life.* 2014.
- 778 16. Zema L, Melocchi A, Maroni A, Gazzaniga A. Three-Dimensional Printing of Medicinal  
779 Products and the Challenge of Personalized Therapy. *J Pharm Sci.* 2017;106(7):1697-  
780 1705.
- 781 17. International clinical trials registry platform search portal. <http://apps.who.int/trialsearch/>.  
782 Accessed February 4, 2019.
- 783 18. Clinicaltrials.gov. <https://clinicaltrials.gov/>. Accessed February 4, 2019.
- 784 19. PROSPERO: International prospective register of systematic reviews.  
785 <https://www.crd.york.ac.uk/prospero/>. Accessed February 3, 2019.
- 786 20. Gilbert F, O'Connell CD, Mladenovska T, Dodds S. [USE THIS ONE] Print Me an  
787 Organ? Ethical and Regulatory Issues Emerging from 3D Bioprinting in Medicine. *Sci*  
788 *Eng Ethics.* 2018;24(1):73-91.
- 789 21. Datta P, Barui A, Wu Y, Ozbolat V, Moncal KK, Ozbolat IT. Essential steps in bioprinting:  
790 From pre- to post-bioprinting. *Biotechnol Adv.* 2018;36(5):1481-1504.
- 791 22. Lieben L. Regenerative medicine: The future of 3D printing of human tissues is taking  
792 shape.[Erratum appears in Nat Rev Rheumatol. 2016 Apr;12(4):191]. *Nature Reviews*  
793 *Rheumatology.* 2016;12(4):191.
- 794 23. Thakur PC, Cabrera DD, DeCarolis N, Boni AA. Innovation and commercialization  
795 strategies for three-dimensional-bioprinting technology: A lean business model  
796 perspective. *J Commer Biotechnol.* 2018;24(1):78-87.

- 797 24. Fraser A. 3D Printing Humans: A Quick Review of 3D Bioprinters. 2018;  
798 <http://bionics.ubc.ca/2018/08/03/3d-printing-humans-a-quick-review-of-3d-bioprinters/>.
- 799 25. Mason J. Focus On: 3-D Printing. *Health Technology Update*. 2016(17).
- 800 26. ECRI Institute. *3-D printing in medicine: an introduction*. April 4, 2018 2018.
- 801 27. Dawood A, Marti Marti B, Sauret-Jackson V, Darwood A. 3D printing in dentistry. *Br Dent*  
802 *J*. 2015;219(11):521-529.
- 803 28. Malik HH, Darwood AR, Shaunak S, et al. Three-dimensional printing in surgery: a  
804 review of current surgical applications. *J Surg Res*. 2015;199(2):512-522.
- 805 29. Gokuldoss PK, Kolla S, Eckert J. Additive Manufacturing Processes: Selective Laser  
806 Melting, Electron Beam Melting and Binder Jetting—Selection Guidelines. *Materials*  
807 *(Basel)*. 2017;10(6):672.
- 808 30. Wong KV, Hernandez A. A review of additive manufacturing. *ISRN Mechanical*  
809 *Engineering*. 2012;2012.
- 810 31. Turksen K. *Bioprinting in regenerative medicine*. Springer; 2015.
- 811 32. Baumers M, Tuck C, Hague R. Selective heat sintering versus laser sintering:  
812 comparison of deposition rate, process energy consumption and cost performance.  
813 Paper presented at: Solid Freeform Fabrication Symposium2015.
- 814 33. Ripley B, Levin D, Kelil T, et al. 3D printing from MRI Data: Harnessing strengths and  
815 minimizing weaknesses. *J Magn Reson Imaging*. 2017;45(3):635-645.
- 816 34. Standing Senate Committee on Social Affairs, Science and Technology. Challenge  
817 ahead : integrating robotics, artificial intelligence and 3D printing technologies into  
818 Canada's healthcare systems. Ottawa (ON): Canada Senate; 2017:  
819 <http://publications.gc.ca/site/eng/9.846477/publication.html>. Accessed 2018 May 24.
- 820 35. The Victoria Hand Project. <https://www.victoriahandproject.com/>.
- 821 36. Precision ADM. <https://www.precisionadm.com/>
- 822 37. Living Cell Imaging Resource Lab. <https://snyder.ucalgary.ca/imaging/contact-us>.
- 823 38. Kinsella Lab. <http://kinsella.lab.mcgill.ca/>.
- 824 39. Institute for Reconstructive Sciences in Medicine.  
825 <https://www.covenanthealth.ca/media/122141/research-excellence-irms-2016jan07.pdf>.
- 826 40. CBC News. Ottawa Hospital opens 1st medical 3D printing program of its kind in  
827 Canada. 2017; [https://www.cbc.ca/news/canada/ottawa/ottawa-hospital-medical-3d-](https://www.cbc.ca/news/canada/ottawa/ottawa-hospital-medical-3d-printing-1.3967350)  
828 [printing-1.3967350](https://www.cbc.ca/news/canada/ottawa/ottawa-hospital-medical-3d-printing-1.3967350).
- 829 41. Aspect Biosystems Ltd. Home. 2017; <https://www.aspectbiosystems.com/>.
- 830 42. Additive Design in Surgical Solutions Centre (ADEISS). Home. 2018; <http://adeiss.ca/>.
- 831 43. Adaptiiv. <https://www.adaptiiv.com/>
- 832 44. Canada Makes. Quebec to Open Its First Medical 3D Printing Center;  
833 <http://canadamakes.ca/quebec-open-first-medical-3d-printing-center/>.
- 834 45. Javelin Technologies Inc. Home. 2018; <https://www.javelin-tech.com/3d/>.
- 835 46. Canada Makes. About Canada Makes. 2018; <http://canadamakes.ca/about/>.
- 836 47. Health Canada. Notice: Upcoming Guidance Development on the Licensing  
837 Requirements for 3D-Printed Devices. 2018; [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/3d-printing-notice.html)  
838 [canada/services/drugs-health-products/medical-devices/activities/announcements/3d-](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/3d-printing-notice.html)  
839 [printing-notice.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/3d-printing-notice.html). Accessed August 29, 2018.
- 840 48. Health Canada. Draft Guidance Document - Licensing Requirements for Implantable  
841 Medical Devices Manufactured by 3D Printing. 2018; [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/notice-licensing-requirements-implantable-3d-printing/draft-guidance-document.html)  
842 [canada/services/drugs-health-products/medical-](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/notice-licensing-requirements-implantable-3d-printing/draft-guidance-document.html)  
843 [devices/activities/announcements/notice-licensing-requirements-implantable-3d-](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/notice-licensing-requirements-implantable-3d-printing/draft-guidance-document.html)  
844 [printing/draft-guidance-document.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/notice-licensing-requirements-implantable-3d-printing/draft-guidance-document.html).
- 845 49. AdvaMed Calls for Revisions to Health Canada Guidance on 3D-Printed Implantable  
846 Devices. 2019.
- 847 50. Statement by FDA Commissioner Scott Gottlieb, M.D., on FDA ushering in new era of  
848 3D printing of medical products; provides guidance to manufacturers of medical devices  
849 [press release]. 2017.

- 850 51. FDA. Emerging Technology Program. 2018;  
851 [https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/uc](https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm523228.htm)  
852 [m523228.htm](https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm523228.htm).
- 853 52. Davies C, Baird L, Jacobson M, et al. 3D printing of medical devices: when a novel  
854 technology meets traditional legal principles. *White paper Life Sciences Industry Group*  
855 [http://www](http://www.reedsmith.com/files/Publication/130448b9-7565-4295-a697-5c5d7c6eb516/Presentation/PublicationAttachment/9ba9b53c-2009-488d-ba91-5cc5a19a38f7/3d-printing-white-paper_79444049.pdf)  
856 [reedsmith.com/files/Publication/130448b9-7565-4295-a697-](http://www.reedsmith.com/files/Publication/130448b9-7565-4295-a697-5c5d7c6eb516/Presentation/PublicationAttachment/9ba9b53c-2009-488d-ba91-5cc5a19a38f7/3d-printing-white-paper_79444049.pdf)  
857 [5c5d7c6eb516/Presentation/PublicationAttachment/9ba9b53c-2009-488d-ba91-](http://www.reedsmith.com/files/Publication/130448b9-7565-4295-a697-5c5d7c6eb516/Presentation/PublicationAttachment/9ba9b53c-2009-488d-ba91-5cc5a19a38f7/3d-printing-white-paper_79444049.pdf)  
858 [5cc5a19a38f7/3d-printing-white-paper\\_79444049.pdf](http://www.reedsmith.com/files/Publication/130448b9-7565-4295-a697-5c5d7c6eb516/Presentation/PublicationAttachment/9ba9b53c-2009-488d-ba91-5cc5a19a38f7/3d-printing-white-paper_79444049.pdf) Accessed August. 2015;1:2016.
- 859 53. van Schothorst M, Weeda J, Schiffers K, et al. Study on the regulation of advanced  
860 therapies in selected jurisdictions. *European Commission*. 2014.
- 861 54. Martelli N, Serrano C, van den Brink H, et al. Advantages and disadvantages of 3-  
862 dimensional printing in surgery: A systematic review. *Surgery*. 2016;159(6):1485-1500.
- 863 55. Lal H, Patralekh MK. 3D printing and its applications in orthopaedic trauma: A  
864 technological marvel. *J*. 2018;9(3):260-268.
- 865 56. Witowski J, Sitkowski M, Zuzak T, et al. From ideas to long-term studies: 3D printing  
866 clinical trials review. *Int J Comput Assist Radiol Surg*. 2018;13(9):1473-1478.
- 867 57. Trenfield SJ, Madla CM, Basit AW, Gaisford S. The shape of things to come: Emerging  
868 applications of 3D printing in healthcare. *AAPS Advances in the Pharmaceutical*  
869 *Sciences Series*. 2018;31:1-19.
- 870 58. Hoang D, Perrault D, Stevanovic M, Ghiassi A. Surgical applications of three-  
871 dimensional printing: a review of the current literature & how to get started. *Ann*.  
872 2016;4(23):456.
- 873 59. Anderson J, Wealleans J, Ray J. Endodontic applications of 3D printing. *Int Endod J*.  
874 2018;51(9):1005-1018.
- 875 60. Nayar S, Bhuminathan S, Bhat WM. Rapid prototyping and stereolithography in  
876 dentistry. *J Pharm Bioallied Sci*. 2015;7(Suppl 1):S216-219.
- 877 61. Alharbi N, Wismeijer D, Osman RB. Additive Manufacturing Techniques in  
878 Prosthodontics: Where Do We Currently Stand? A Critical Review. *Int J Prosthodont*.  
879 2017;30(5):474-484.
- 880 62. Bilgin MS, Baytaroglu EN, Erdem A, Dilber E. A review of computer-aided  
881 design/computer-aided manufacture techniques for removable denture fabrication. *Eur J*  
882 *Dent*. 2016;10(2):286-291.
- 883 63. Diment LE, Thompson MS, Bergmann JH. Three-dimensional printed upper-limb  
884 prostheses lack randomised controlled trials: A systematic review. *Prosthet Orthot Int*.  
885 2018;42(1):7-13.
- 886 64. Tack P, Victor J, Gemmel P, Annemans L. 3D-printing techniques in a medical setting: A  
887 systematic literature review. *Biomed Eng Online*. 2016;15 (1) (no pagination)(115).
- 888 65. Randazzo M, Pisapia JM, Singh N, Thawani JP. 3D printing in neurosurgery: A  
889 systematic review. *Surg Neurol Int*. 2016;7(Suppl 33):S801-S809.
- 890 66. Wilcox B, Mobbs RJ, Wu AM, Phan K. Systematic review of 3D printing in spinal  
891 surgery: the current state of play. *J*. 2017;3(3):433-443.
- 892 67. Vaishya R, Patralekh MK, Vaish A, Agarwal AK, Vijay V. Publication trends and  
893 knowledge mapping in 3D printing in orthopaedics. *J*. 2018;9(3):194-201.
- 894 68. Xie L, Chen C, Zhang Y, Zheng W, Chen H, Cai L. Three-dimensional printing assisted  
895 ORIF versus conventional ORIF for tibial plateau fractures: A systematic review and  
896 meta-analysis. *International Journal Of Surgery*. 2018;57:35-44.
- 897 69. Tam CHA, Chan YC, Law Y, Cheng SWK. The Role of Three-Dimensional Printing in  
898 Contemporary Vascular and Endovascular Surgery: A Systematic Review. *Ann Vasc*  
899 *Surg*. 2018;53:243-254.
- 900 70. Louvrier A, Marty P, Barrabe A, et al. How useful is 3D printing in maxillofacial surgery?  
901 *J Stomatol Oral Maxillofac Surg*. 2017;118(4):206-212.
- 902 71. Lin HH, Lonc D, Lo LJ. 3D printing in orthognathic surgery - A literature review. *J*  
*Formos Med Assoc*. 2018;02:02.

- 903 72. Bauermeister AJ, Zuriarrain A, Newman MI. Three-Dimensional Printing in Plastic and  
904 Reconstructive Surgery: A Systematic Review. *Ann Plast Surg.* 2016;77(5):569-576.
- 905 73. Choi JW, Kim N. Clinical application of three-dimensional printing technology in  
906 craniofacial plastic surgery. *Arch.* 2015;42(3):267-277.
- 907 74. Perica ER, Sun Z. A Systematic Review of Three-Dimensional Printing in Liver Disease.  
908 *J Digit Imaging.* 2018;31(5):692-701.
- 909 75. Witowski JS, Coles-Black J, Zuzak TZ, et al. 3D Printing in Liver Surgery: A Systematic  
910 Review. *Telemed J E Health.* 2017;23(12):943-947.
- 911 76. Sun Z, Liu D. A systematic review of clinical value of three-dimensional printing in renal  
912 disease. *Quant.* 2018;8(3):311-325.
- 913 77. Parikh N, Sharma P. Three-Dimensional Printing in Urology: History, Current  
914 Applications, and Future Directions. *Urology.* 2018;21:21.
- 915 78. Manning TG, O'Brien JS, Christidis D, et al. Three dimensional models in uro-oncology:  
916 a future built with additive fabrication. *World J Urol.* 2018;36(4):557-563.
- 917 79. Lau I, Sun Z. Three-dimensional printing in congenital heart disease: A systematic  
918 review. *J Med Radiat Sci.* 2018;65(3):226-236.
- 919 80. Chao I, Young J, Coles-Black J, Chuen J, Weinberg L, Rachbuch C. The application of  
920 three-dimensional printing technology in anaesthesia: a systematic review. *Anaesthesia.*  
921 2017;72(5):641-650.
- 922 81. Trombetta R, Inzana JA, Schwarz EM, Kates SL, Awad HA. 3D Printing of Calcium  
923 Phosphate Ceramics for Bone Tissue Engineering and Drug Delivery. *Ann Biomed Eng.*  
924 2017;45(1):23-44.
- 925 82. Tarassoli SP, Jessop ZM, Al-Sabah A, et al. Skin tissue engineering using 3D  
926 bioprinting: An evolving research field. *Journal of Plastic, Reconstructive & Aesthetic*  
927 *Surgery: JPRAS.* 2018;71(5):615-623.
- 928 83. Aprecia Pharmaceuticals LLC. Zipdose Technology. 2018;  
929 <https://www.aprecia.com/technology/zipdose>. Accessed January 8, 2019.
- 930 84. Ursan ID, Chiu L, Pierce A. Three-dimensional drug printing: a structured review. *Journal*  
931 *of the American Pharmacists Association: JAPhA.* 2013;53(2):136-144.
- 932 85. Vakharia VN, Vakharia NN, Hill CS. Review of 3-Dimensional Printing on Cranial  
933 Neurosurgery Simulation Training. *World Neurosurg.* 2016;88:188-198.
- 934 86. Filippou V, Tsoumpas C. Recent advances on the development of phantoms using 3D  
935 printing for imaging with CT, MRI, PET, SPECT, and ultrasound. *Med Phys.* 2018;22:22.
- 936 87. Rogers-Vizena CR, Sporn SF, Daniels KM, Padwa BL, Weinstock P. Cost-Benefit  
937 Analysis of Three-Dimensional Craniofacial Models for Midfacial Distraction: A Pilot  
938 Study. *Cleft Palate Craniofac J.* 2017;54(5):612-617.
- 939 88. Mendis D, Lemley M, Rimmer M. The future of printcrime: Intellectual property,  
940 innovation law, and 3D printing. *3D Printing and Beyond: The Intellectual Property and*  
941 *Legal Implications Surrounding 3D Printing and Emerging Technology:* Edward Elgar  
942 Publishing Limited; 2019.
- 943 89. Haddow G, Vermeulen N. So, What is Not to Like about 3D Bioprinting? In: *Ethics B-*  
944 *JoM,* ed2017.
- 945 90. Gilbert F, Viana JNM, O'Connell CD, Dodds S. Enthusiastic portrayal of 3D bioprinting in  
946 the media: Ethical side effects. *Bioethics.* 2018;32(2):94-102.
- 947 91. Neely EL. The risks of revolution: Ethical dilemmas in 3D printing from a US perspective.  
948 *Sci Eng Ethics.* 2016;22(5):1285-1297.
- 949 92. Vermeulen N, Haddow G, Seymour T, Faulkner-Jones A, Shu W. 3D bioprint me: a  
950 socioethical view of bioprinting human organs and tissues. *J Med Ethics.*  
951 2017:medethics-2015-103347.
- 952 93. Marchioli G, van Gorp L, Van Krieken P, et al. Fabrication of three-dimensional  
953 bioplotting hydrogel scaffolds for islets of Langerhans transplantation. *Biofabrication.*  
954 2015;7(2):025009.

- 955 94. Wolinsky H. Printing organs cell-by-cell: 3-D printing is growing in popularity, but how  
956 should we regulate the application of this new technology to health care? *EMBO reports*.  
957 2014:e201439207.
- 958 95. Munsie M, Hyun I. A question of ethics: selling autologous stem cell therapies flaunts  
959 professional standards. *Stem cell research*. 2014;13(3):647-653.
- 960 96. Gilbert F. A threat to autonomy? The intrusion of predictive brain implants. *AJOB*  
961 *Neurosci*. 2015;6(4):4-11.
- 962 97. Gilbert F. The burden of normality: from 'chronically ill' to 'symptom free'. New ethical  
963 challenges for deep brain stimulation postoperative treatment. *J Med Ethics*.  
964 2012;38(7):408-412.
- 965 98. Bretzner F, Gilbert F, Baylis F, Brownstone RM. Target populations for first-in-human  
966 embryonic stem cell research in spinal cord injury. *Cell stem cell*. 2011;8(5):468-475.
- 967 99. Hess P. Intracranial stem cell-based transplantation: Reconsidering the ethics of phase  
968 1 clinical trials in light of irreversible interventions in the brain. *AJOB Neurosci*.  
969 2012;3(2):3-13.
- 970 100. ECRI Institute. Use of Three-dimensional Printed Anatomic Models for Cardiovascular  
971 and Neurologic Surgical Planning. 2018.
- 972 101. AETNA. Stereolithography (Policy no. 613). 2017;  
973 [http://www.aetna.com/cpb/medical/data/600\\_699/0613.html](http://www.aetna.com/cpb/medical/data/600_699/0613.html).
- 974 102. EUnetHTA. Custom-made or customisable 3D printed implants and cutting guides  
975 versus non-3D printed standard implants and cutting guides for improving outcome in  
976 patients undergoing knee, maxillofacial, or cranial surgery. 2018.
- 977 103. Chesbrough HW. Bringing open innovation to services. *MIT sloan management review*.  
978 2011;52(2):85.
- 979 104. Javid M, Haleem A. 4D printing applications in medical field: A brief review. *Clinical*  
980 *Epidemiology and Global Health*. 2018.

981